Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Page 1
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT).
Verardi F, Maul LV, Borsky K, Steinmann S, Rosset N, Pons HO, Sorbe C, Yawalkar N, Micheroli R, Egeberg A, Thyssen JP, Heidemeyer K, Boehncke WH, Conrad C, Cozzio A, Pinter A, Kündig T, Navarini AA, Maul JT. Verardi F, et al. Among authors: yawalkar n. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):719-731. doi: 10.1111/jdv.19730. Epub 2023 Dec 12. J Eur Acad Dermatol Venereol. 2024. PMID: 38084852
There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies. OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs). ...
There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies. OBJECTIVES: To examine the re …
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis.
Benzaquen M, Munshi M, Bossart S, Feldmeyer L, Emelianov V, Yawalkar N, Cazzaniga S, Heidemeyer K. Benzaquen M, et al. Among authors: yawalkar n. Bioengineering (Basel). 2022 Aug 13;9(8):387. doi: 10.3390/bioengineering9080387. Bioengineering (Basel). 2022. PMID: 36004912 Free PMC article.
However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug's effectiveness. The long-term effects of DS with adalimumab in psoriatic patients have not been reported. The goal of our study was to evaluate the l …
However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug's effectiveness. …
Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
Distel J, Cazzaniga S, Seyed Jafari SM, Emelianov V, Schlapbach C, Yawalkar N, Heidemeyer K. Distel J, et al. Among authors: yawalkar n. Dermatology. 2022;238(2):267-275. doi: 10.1159/000515763. Epub 2021 Jun 4. Dermatology. 2022. PMID: 34091455
BACKGROUND: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug survival of patients treated with apremilast are limited. ...
BACKGROUND: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the treatment of moderate to severe psoriasis. Long-term …
The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients.
Fan Z, Zhang Z, Huang Q, Han L, Fang X, Yang K, Wu S, Zheng Z, Yawalkar N, Wang Z, Yan K. Fan Z, et al. Among authors: yawalkar n. Dermatology. 2021;237(4):579-587. doi: 10.1159/000514072. Epub 2021 Feb 12. Dermatology. 2021. PMID: 33582672
After adjustment for potential confounders, patients with rs11960458 TT/CT genotype (at 12 weeks: OR 0.483, 95% CI 0.245-0.951, p = 0.035; at 1 year: OR 0.483, 95% CI 0.280-0.833, p = 0.009) were significantly more likely to not respond to MTX both on the short-term and lo …
After adjustment for potential confounders, patients with rs11960458 TT/CT genotype (at 12 weeks: OR 0.483, 95% CI 0.245-0.951, p = 0.035; a …
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
Maul JT, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, Yawalkar N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA. Maul JT, et al. Among authors: yawalkar n. Dermatology. 2016;232(6):640-647. doi: 10.1159/000452740. Epub 2017 Jan 12. Dermatology. 2016. PMID: 28076860 Free article.
BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. ...
BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and ef …
Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M, Oberholzer PA, Baumgartner M, Gadaldi K, Yawalkar N, Hunger RE. Gautschi M, et al. Among authors: yawalkar n. J Am Acad Dermatol. 2016 Jan;74(1):81-87.e1. doi: 10.1016/j.jaad.2015.08.031. Epub 2015 Oct 23. J Am Acad Dermatol. 2016. PMID: 26601565 Free article. Clinical Trial.
BACKGROUND: More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM). OBJECTIVE: We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM w …
BACKGROUND: More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM). O …
Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients.
Zecca C, Yawalkar N, Gobbi C. Zecca C, et al. Among authors: yawalkar n. Patient Prefer Adherence. 2012;6:565-7. doi: 10.2147/PPA.S33727. Epub 2012 Aug 8. Patient Prefer Adherence. 2012. PMID: 22927749 Free PMC article.
BACKGROUND: The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence. METHODS: Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the establi …
BACKGROUND: The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence. METHODS …
Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker.
Lee HY, Pelivani N, Beltraminelli H, Hegyi I, Yawalkar N, Borradori L. Lee HY, et al. Among authors: yawalkar n. Dermatology. 2011;222(4):304-10. doi: 10.1159/000329428. Epub 2011 Jul 15. Dermatology. 2011. PMID: 21757882 Free article. Review.
We here describe an APF-like pustular eruption predominantly affecting the scalp, face and trunk, occurring during long-term infliximab treatment for Crohn's disease. Immunohistochemical staining of skin biopsy specimens for myxovirus resistance protein A, a marker for typ …
We here describe an APF-like pustular eruption predominantly affecting the scalp, face and trunk, occurring during long-term inflixim …